Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer

被引：34

作者：

Solomon, Benjamin J. ^{[1
]}

Zhou, Cai Cun ^{[2
]}

Drilon, Alexander ^{[3
]}

Park, Keunchil ^{[4
]}

Wolf, Jurgen ^{[5
]}

Elamin, Yasir ^{[6
]}

Davis, Hannah M. ^{[7
]}

Soldatenkova, Victoria ^{[7
]}

Sashegyi, Andreas ^{[7
]}

Lin, Aimee Bence ^{[7
]}

Lin, Boris K. ^{[7
]}

Loong, Herbert H. ^{[8
]}

Novello, Silvia ^{[9
]}

Arriola, Edurne ^{[10
]}

Perol, Maurice ^{[11
]}

Goto, Koichi ^{[12
]}

Santini, Fernando C. ^{[13
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[4] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Eli Lilly & Co, Indianapolis, IN 46225 USA

[8] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[9] Univ Turin, Dept Oncol, AOU San Luigi Orbassano, Turin, Italy

[10] Hosp del Mar, Barcelona, Spain

[11] Leon Berard Canc Ctr Lyon, Lyon, France

[12] Natl Canc Ctr Hosp East, Chiba, Japan

[13] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 07期

关键词：

non-small-cell lung cancer; Phase III trial; RET fusion-positive; RET kinase inhibitor; RET rearrangement; selpercatinib; targeted therapy; ALK; REARRANGEMENTS; EFFICACY; FUSIONS; IPILIMUMAB; MUTATIONS; BLOCKADE; NSCLC; EGFR; BRAF;

D O I：

10.2217/fon-2020-0935

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.

引用

页码：763 / 773

页数：11

共 50 条

[21] Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab [J].

Freeman, A. T. ;

Lesperance, M. ;

Wai, E. S. ;

Croteau, N. S. ;

Fiorino, L. ;

Geller, G. ;

Brooks, E. G. ;

Poonja, Z. ;

Fenton, D. ;

Irons, S. ;

Ksienski, D. .

CURRENT ONCOLOGY, 2020, 27 (02) :76-82

[22] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[23] Targeted therapy of RET fusion-positive non-small cell lung cancer [J].

Shen, Zixiong ;

Qiu, Binxu ;

Li, Lin ;

Yang, Bo ;

Li, Guanghu .

FRONTIERS IN ONCOLOGY, 2022, 12

[24] Maintenance chemotherapy for non-small-cell lung cancer [J].

Kim, Young Hak ;

Mishima, Michiaki .

CANCER TREATMENT REVIEWS, 2011, 37 (07) :505-510

[25] Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer [J].

McCoach, Caroline E. ;

Yu, Aiming ;

Gandara, David R. ;

Riess, Jonathan W. ;

Vang, Daniel P. ;

Li, Tiahong ;

Lara, Primo N. ;

Gubens, Matthew ;

Lara, Frances ;

Mack, Philip C. ;

Beckett, Laurel A. ;

Kelly, Karen .

JCO PRECISION ONCOLOGY, 2021, 5 :177-190

[26] Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis [J].

Huo, Gengwei ;

Liu, Wenjie ;

Kang, Shuo ;

Chen, Peng .

FRONTIERS IN PHARMACOLOGY, 2023, 14

[27] Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer [J].

Bhandari, Naleen Raj ;

Hess, Lisa M. ;

Han, Yimei ;

Zhu, Yajun E. ;

Sireci, Anthony N. .

IMMUNOTHERAPY, 2021, 13 (11) :893-904

[28] Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer [J].

Song, Qi ;

Li, Jie ;

Xiong, Qi ;

Long, Ya Ping ;

Yang, Bo ;

Dong, Zhou Huan ;

Liang, Chao Yang ;

Yang, Bo .

IMMUNOTHERAPY, 2023, 15 (11) :809-817

[29] Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407 [J].

Sugawara, Shunichi ;

Tanaka, Kentaro ;

Imamura, Fumio ;

Yamamoto, Nobuyuki ;

Nishio, Makoto ;

Okishio, Kyoichi ;

Hirashima, Tomonori ;

Tanaka, Hiroshi ;

Fukuhara, Tatsuro ;

Nakahara, Yasuharu ;

Kurata, Takayasu ;

Katakami, Nobuyuki ;

Okada, Morihito ;

Horinouchi, Hidehito ;

Udagawa, Hibiki ;

Kasahara, Kazuo ;

Satouchi, Miyako ;

Saka, Hideo ;

Tokito, Takaaki ;

Hosomi, Yukio ;

Aoe, Keisuke ;

Kishi, Kazuma ;

Ohashi, Kadoaki ;

Yokoyama, Takuma ;

Adachi, Noriaki ;

Noguchi, Kazuo ;

Schwarzenberger, Paul ;

Kato, Terufumi .

CANCER SCIENCE, 2023, 114 (08) :3330-3341

[30] Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial [J].

Lu, Shun ;

Cheng, Ying ;

Huang, Dingzhi ;

Sun, Yuping ;

Wu, Lin ;

Zhou, Chengzhi ;

Zhou, Jianying ;

Guo, Ye ;

Shao, Jingxin ;

Zhang, Wanli .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17

← 1 2 3 4 5 →